Results from a study on Repros Therapeutic Inc.’s experimental testosterone drug Androxal will be delayed because the drug company is removing some patients from the trial. Androxal was being tested as a treatment for secondary hypogonadism, a condition in which the testes do not produce enough testosterone. Researchers found that at one testing site study participants had lower starting sperm counts and testosterone levels than patients at other study sites. Repros decided to remove those 40 patients from the trial and replace them with other patients. The drug company says it now expects to have data on Androxal sometime during ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.